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Introduction
The World Health Organization (WHO) described 
Coronavirus 2019 (COVID-19) as a public health 
emergency. The international concern of COVID-19 
is more in comparison to Severe Acute Respiratory 
Syndrome (SARS), which previously was pandemic in 
2003  [1]. Coronaviruses are important pathogens that 
can affect the lower respiratory tract in humans and 
can cause diseases ranging from a simple cold to severe 
infection with up to 50% lethality [2]. The COVID-19 is 
a highly contagious infectious disease and one infected 
person can infect an average of three other people  [3] 
which is higher than that for SARS (1.7-1.9) and MERS 
(<  1), suggesting that SARS-CoV-2 has a greater 
potential for being outbreak. Evidence suggests that there 
are many similarities between COVID-19 and SARS. 
About 79.5% of the similarities in the genome sequence 
of these two viruses have been reported [4]. COVID-19 
can spread in the community more easily than MERS 
and SARS because of the less severe clinical picture of 
it  [5]. Although the disease is mild in most people, in 
some patients, especially those with other underlying 
diseases, there may be a respiratory failure, arrhythmias, 
shock, Kidney failure, cardiovascular damage, or liver 
failure  [6, 7]. Currently, there is no effective antiviral 
treatment for the disease and only supportive care may 
be helpful [7] The case fatality rate (CFR) of COVID-19 
was reported to be 3.8% but it can differ in patients 
who have comorbidities  [8]. The CFR of COVID-19 
is lower than that of SARS and that of MERS[5]. The 
most common symptoms are fever, cough, and myalgia 
or fatigue  [9]. Although the clinical symptoms of the 
disease are nonspecific, understanding the symptoms is 
essential. Patient with fever and upper respiratory tract 
symptoms with lymphopenia or leukopenia should be 
considered as suspected  [9] Patients may present with 
diarrhea a few days before the fever. A slight number of 
patients may report a headache  [10]. Diarrhea is more 
common in SARS [5].
Combining the results of studies that have focused on 
the prevalence of COVID-19 related symptoms could 
be helpful in the best identification and diagnosis of 
infection. Because of the importance of symptoms in 
the identification of COVID-19 infection the current 
study was aimed to estimate the prevalence of Clinical 
Symptoms of COVID-19 in a systematic review and 
meta-analysis.
Introduction. COVID-19 is an emerging infectious disease. The 
study about features of this infection could be very helpful in bet-
ter knowledge about this infectious disease. The current system-
atic review and meta-analysis were aimed to estimate the preva-
lence of clinical symptoms of COVID-19 in a systematic review 
and meta-analysis.
Methods. A systematic review using Medline/PubMed, Scopus, 
and Google scholar has been conducted. In the current systematic 
review and meta-analysis, the articles published in the period Janu-
ary 1, 2020, to April 2, 2020, written in English and reporting clini-
cal symptoms of COVID-19 was reviewed. To assess, the presence 
of heterogeneity, the Cochran’s Q statistic, the I2 index, and the tau-
squared test were used. Because of significant heterogeneity between 
the studies the random-effects model with 95% CI was used to calcu-
late the pooled estimation of each symptom prevalence.
Results. The most common symptoms in COVID-19 patients 
include: Fever 81.2% (95% CI: 77.9-84.4); Cough: 58.5% (95% 
CI:  54.2-62.8); Fatigue 38.5% (95% CI: 30.6-45.3); Dysp-
nea: 26.1% (95% CI: 20.4-31.8); and the Sputum: 25.8% (95% 
CI: 21.1-30.4). Based on the meta-regression results, the sample 
size used in different studies did not have a significant effect on the 
final estimate value (P > 0.05).
Conclusions. Considering the main symptoms of COVID-19 such 
as Fever, Cough, Fatigue, and Dyspnea can have a key role in 
early detection of this disease and prevent the transmission of the 
disease to other people.
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Summary




All articles published in the period January 1, 2020, to 
April 2, 2020, written in English and reporting clinical 
symptoms of COVID-19 was reviewed. Review articles 
as well as articles that lacked original data or reported 
incomplete data were excluded.
Information sources and search strategy
We conducted a systematic review using Medline/
PubMed, Scopus and Google scholar. The following 
search terms used: “Clinical features”, “COVID-19”, 
“coronavirus disease 2019”, “coronavirus disease-19”, 
“2019 novel coronavirus disease”, “severe acute 
respiratory syndrome coronavirus”, “clinical symptoms”, 
“clinical characteristics” and “clinical manifestations”. 
The searches were concluded by April 2, 2020, and 
two researchers independently assessed search results. 
References of related papers were also searched for 
other relevant articles to enhance the search strategy.
Study selection
After performing the search strategy some records were 
excluded because of Duplicates and unrelated. After that, 
the records screened based on abstracts and titles. The 
full text of related articles was then assessed according 
to the inclusion and exclusion criteria. Observational 
studies that reported clinical symptoms were included in 
the meta-analysis.
Data collection process and data items
Data including the type and date of publication, 
country, the sample size, age, and clinical symptoms 
of COVID-19 were extracted independently by two 
authors. A third person checked the article list and data 
extractions to ensure there were no duplicate articles and 
also resolved discrepancies about study inclusion.
Assessment of methodological quality
To assess the study quality of the case series studies 
the Institute of Health Economics (IHE) was used [11]. 
Also, the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) checklist for 
observational studies was used assessment quality of the 
cross-sectional and cohort studies. 
Meta-regression analysis
To assess the effect of sample size on pooled estimations 
the meta-regression analysis was used. 
Statistical approach
To assessment, the presence of heterogeneity, the 
Cochran’s Q statistic, the I2 index, and the tau-squared 
test were used. Due to the difference in the age of patients, 
we perform subgroup analyzes in different age groups. 
Because of the presence, the significant heterogeneity 
between the studies the random-effects model with 
95% CI was used to calculate the pooled estimation of 
symptoms prevalence. The data were analyzed using 
stata version 11.0.
Results 
In the current systematic review and meta-analysis, 
54  studies that estimated the symptoms related to 
COVID-19 were included in the final analysis (Tab. I). 
After searching PubMed and Google Scholar electronic 
databases, 1,498 possibly relevant articles were 
identified; 1,397 articles were removed due to unrelated 
to study purpose and duplication. Of the remaining 
101 articles, 45 were excluded after screening based on 
abstract and title and 2 articles removed because of lack 
of needed information. Finally, 54 articles were included 
in the final meta-synthesis (Fig. 1).
Tab. I. Characteristics of the included studies on effective factors on 
mortality COVID-19, 2020. 
Id First author Country Design
Sample 
size
1 Dawei Wang [12] China Case series  138
2 Chaolin [13] China Cross-sectional 41
3 Chen [14] China Cross-sectional 99
4 Chung [15] China Cross-sectional 21
5 Chen [16] China Cross-sectional 29
6 Wang [12] China Cross-sectional 138
7 Kui [17] China Cross-sectional 137





10 Li et al. [20] China Case series 24
11 Feng [21] China Case series 21
12 Zhang [22] China Case series 9
13 Feng [23] China Case series 15
14 Wang [24] China Cross-sectional 34









18 Wen Zhao [28] China Cohort study 77
19 Wenjie Yang [29] China Cohort study 85
20 Matt Arentz [30] USA Case series 21
21 Ying Huang [31] China Retrospective 36
22
G Jian-ya Lei Liu 
[32]
China Retrospective 51
23 Tao Chen [4] China Cohort 274
24 jin Zhang [33] China Cross-sectional 242
25 Shijiao Yan [34] China Retrospective 168
26 Jian Wu [35] China Retrospective 80
27 Yang Xu [36] China Retrospective 69





30 Youbin Liu [39] China Retrospective 291
31 Yanli Liu [40] China Retrospective 109
continues
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According to the results of the analysis, the most 
common symptoms in patients with coronavirus include:
• Fever 81.2% (95% CI: 77.9-84.4); 
• Cough: 58.5% (95% CI: 54.2-62.8); 
• Fatigue: 38.5% (95% CI: 30.6-45.3); 
• Dyspnea: 26.1% (95% CI: 20.4-31.8); 
• and the presence of Sputum: 25.8% (95% CI: 21.1-
30.4). 
Other results are shown in Table II and Figure 2. Figure 2 
presents the pooled estimation of some symptoms among 
COVID-19 patients. 
Meta-regression analysis 
Based on the meta-regression results, the sample size 
used in different studies did not have a significant 
effect on the final estimate value (P > 0.05). 
The distribution of the estimated prevalence of 
different symptoms according to sample sizes as 
shown in Figure 3.
The diagrams below show the percentage distribution 
of symptom estimation based on the volume of 
different samples. 
Based on these charts, the estimated amount of chest 
pain, cough, dyspnea, hemoptysis, and fever with 
decreasing sample size showed a decreasing trend, 
while other symptoms showed an increasing trend 
with increasing sample size. 
Fig. 1. PRISMA Flow Diagram for included studies in the current meta-analysis.
Tab. I. Characteristics of the included studies on effective factors on 
mortality COVID-19, 2020.
32 Yonghao Xu [41] China Retrospective 45
33 Lang Wang [42] China Cohort 339
34 Zhichao Feng [43] China Cohort 141




Singapore Case series 18
37 Ying Wen [46] China Retrospective 417
38 Jiaqiang Liao [47] China Retrospective 46
39 Xu Chen [48] China Cohort 291
40 Penghui Yang [49] China Cohort 55
41 Jie Liu [50] China Retrospective 64
42 Hang Fu [51] China Cross-sectional 52
43 Heshui Shi [52] China Cross-sectional 81
44 Wei Zhao [53] China Retrospective 101
45 Hua Fan [54] China Cohort 47
46 Ling Hu [55] China Retrospective 323
47 X. Zhao [56] China Cross-sectional 80
48 Zhaowei Chen [57] China Retrospective 89
49 Huijun Chen [58] China Retrospective 9
50 Rachael Pung [59] Singapore Retrospective 17
51 Wanbo Zhu [60] China Retrospective 116
52 Xiaoping Chen [61] China Retrospective 123
53 W. Guan [62] China Cross-sectional 1,099
54 Xi Xu[ 63] China Retrospective 90
follows
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Discussion 
The COVID-19 is a new highly contagious infection that 
threatens people of all countries [64].
The clinical presentation of COVID-19 is wide, from 
asymptomatic infection to severe fatal diseases [14] 
Considering the shortage of diagnostic kits around the 
world this systematic review seems necessary, to find 
the clinical presentation of COVID-19 and using them in 
early diagnosis of this infection [13]. Unfortunately, there 
is no treatment for this virus, and patients’ treatment is 
just focused on supportive care. On the other hand, the 
limited number of critical care centers and mechanical 
ventilation in the world culminates in high concern 
for the health care system [7]. To date, over 1,607,912 
cases have been reported worldwide and from different 
countries [65]. To deal with such an emerging infectious 
disease, there an urgent need to identify and determine 
factors associated with the evolution of the disease and its 
outcomes. In this Systematic Review and Meta-Analysis 
study, we reported the clinical symptoms of COVID-19. 
Although the 2019-nCoV sequence is not the same as 
the other two viruses (SARS-CoV and MERS-CoV) that 
were pandemic in 2003 and 2012, respectively, they are 
somewhat similar in pathogenesis [66, 67]. Cytokines 
may play a role in human coronavirus infection. Indirect 
evidence suggests that in the second phase of 2019-nCoV 
infection: high fever, pneumonia, and hypoxemia occur 
despite a significant reduction in viral load [68]. In this 
systematic review and meta-analysis study, the clinical 
symptoms of COVID-19 were examined to provide a 
better understanding of the disease. The most common 
symptoms were fever and, cough, and fatigue that was 
consistent with the general symptoms of a viral infection 
and pneumonia. Similar to previous studies [25, 62], the 
present study showed that fever in 81.2% of cases, cough in 
58.5% of cases, and fatigue in 38.5% of cases. Fever is the 
most common symptom in patients with COVID-19, but 
not all patients had fever [13, 69]. The fever is an alarming 
sign of the disease, vomiting, and fever (above 39 degrees) 
are usually associated with more severe illness and more 
length of stay in the hospital. Fever is less common in 
COVID-19 than in SARS and MERS [34, 70]. Therefore, 
more attention should be paid to COVID-19 patients who 
do not have fever as a source clue of infection, and if the 
surveillance system relies only on fever in patients, then 
some patients will be missed [71]. Diarrhea, myalgia, 
hemoptysis, and sore throats were less common symptoms 
in this review, these results were similar to those obtained 
for other viruses, such as SARS and MERS [26]. This may 
indicate that COVID-19 can also be classified as a similar 
infection to SARS and MERS infection, which targets 
the cells of the lower respiratory tract system. Although 
nasopharynx is theoretically the first organ infected 
with the COVID-19, a recent study [13] showed that 
infected individuals rarely show present upper respiratory 
symptoms at the onset of the infection. This suggests that 
the virus mostly targets the cells of the lower respiratory 
tract cells [72]. Research and clinical findings suggest that 
SARS-CoV-2 may be colonized in the nasopharynx but 
the immune system cannot identify COVID-19 in the early 
stages. Therefore, the virus can be removed from the body 
with its through natural reactions, including sneezing and 
runny nose. This demonstrates the importance of accurately 
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identifying COVID-19 symptoms at admission. Especially 
considering that studies have suggested the possibility 
of transmission of the disease by a healthy carrier [73]. 
This may be one of the reasons why COVID-19 is more 
contagious than SARS. 
On the other hand, the lower incidence of early respiratory 
symptoms may be due to the presence of a pathogenic 
latency of SARS-CoV-2. Although gastrointestinal 
symptoms, especially diarrhea, were rare in the current 
study, the results of a study have shown that the SARS-
CoV-2 virus can be isolated from the fecal samples of 
patients with gastrointestinal symptoms [74]. In another 
study, the SARS-CoV-2 virus has been isolated in a rectal 
swab of patients whose RT-PCR test results were negative 
with a throat swab sample [44]. Therefore, simultaneously 
sampling from throat and rectal may be useful, especially 
in patients with gastrointestinal symptoms. This review 
has some limitations which should be considered when 
interpreting the results. Most of the available studies for 
inclusion are from China. However the present study was 
done without any language restrictions and based on a 
comprehensive search strategy, only English electronic 
databases were searched; thus, it is likely that some related 
non-English papers have been missed.
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Fig. 3. The distribution of estimated prevalence of symptoms according to different sample sizes (the X and Y axes are the sample size and 
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Conclusions
Due to the rapid spreading of this infection, the lack 
of diagnostic tools, and limited intensive care units in 
the world, the use of other factors such as the clinical 
features of COVID19 can serve to give early warning for 
the appropriate interventions and decrease the number of 
death of COVID-19. So considering the main symptoms 
of COVID-19 such as Fever, cough Fatigue and Dyspnea 
can have a key role in early detection of this disease.
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